(Q40188974)

18 September 2017

title

Posaconazole: a next-generation triazole antifungal (English)

1 reference

18 September 2017

3

Oliver A Cornely

1 reference

18 September 2017

Fedja Farowski

1

1 reference

18 September 2017

Jörg J Vehreschild

series ordinal

2

1 reference

18 September 2017

publication date

1 June 2007

1 reference

18 September 2017

number of pages

13

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

18 September 2017

volume

2

1 reference

18 September 2017

issue

3

1 reference

18 September 2017

page(s)

231-243

1 reference

Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Aspergillosis case-fatality rate: systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Attributable mortality of nosocomial candidemia, revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Zygomycetes in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Zygomycosis: the re-emerging fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Epidemiology and outcome of zygomycosis: a review of 929 reported cases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Anti-Candida drugs--the biochemical basis for their activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Efficacy of SCH56592 in a rabbit model of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Antifungal therapy of murine Aspergillus terreus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Efficacy of posaconazole in a murine model of central nervous system aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Posaconazole therapy of disseminated phaeohyphomycosis in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

In vitro and in vivo activities of posaconazole against Coccidioides immitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Posaconazole prophylaxis in experimental systemic zygomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Disposition of posaconazole following single-dose oral administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Activity of posaconazole in the treatment of central nervous system fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Posaconazole as salvage therapy for zygomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460913.2.3.231

21 January 2018

Identifiers

DOI

10.2217/17460913.2.3.231

1 reference

18 September 2017

1 reference